康复新液联合泮托拉唑对慢性糜烂性胃炎患者炎性因子及胃泌素、胃动素水平的影响

Effect of Kangfuxin Solution Combined with Pantoprazole on the Levels of Inflammatory Factors,Gastrin and Motilin in Patients with Chronic Erosive Gastritis

目的探究康复新液联合泮托拉唑对慢性糜烂性胃炎患者炎性因子及胃泌素、胃动素水平的影响.方法选择本院2021年1月—2022年3月收治的78例慢性糜烂性胃炎患者为研究对象,按随机数字表法分为对照组、观察组,每组39例.对照组采用泮托拉唑治疗,观察组在此基础上采用康复新液治疗,均持续治疗8周.比较两组的临床疗效、炎性因子水平、胃泌素及胃动素水平、安全性.结果观察组的治疗总有效率为94.87%,高于对照组的79.49%,差异有统计学意义(P<0.05).治疗后,观察组的白细胞介素-6、C反应蛋白、肿瘤坏死因子-α水平分别为(25.20±2.49)ng/L、(3.43±0.52)mg/L、(59.83±5.38)ng/L,均低于对照组,组间差异有统计学意义(P<0.05).治疗后,观察组的胃泌素、胃动素水平分别为(162.16±12.65)pg/mL、(302.33±13.19)ng/L,均高于对照组,组间差异有统计学意义(P<0.05).两组的不良反应发生率比较,差异无统计学意义(P>0.05).结论采用康复新液联合泮托拉唑治疗慢性糜烂性胃炎能够有效减轻患者炎症反应,调节胃肠激素,且安全可靠,可于临床推广.

Objective To investigate the effect of Kangfuxin Solution combined with pantoprazole on the levels of inflammatory factors,gastrin and motilin in patients with chronic erosive gastritis.Methods A total of 78 patients with chronic erosive gastritis admitted to our hospital from January 2021 to March 2022 were selected as the research objects and were divided into a control group and an observation group according to random number table method,with 39 cases in each group.The control group was treated with pantoprazole,and the observation group was treated with Kangfuxin Solution on this basis.Both groups were treated for 8 weeks.The clinical efficacy,levels of inflammatory factors,gastrin and motilin,and safety were compared between the two groups.Results The total effective rate of the observation group was 94.87%,which was higher than 79.49%of the control group,the difference was statistically significant(P<0.05).After treatment,the levels of interleukin-6,C-reactive protein and tumor necrosis factor-αin the observation group were(25.20±2.49)ng/L,(3.43±0.52)mg/L and(59.83±5.38)ng/L,respectively,which were lower than those in the control group,and the differences between groups were statistically significant(P<0.05).After treatment,the levels of gastrin and motilin in the observation group were(162.16±12.65)pg/mL and(302.33±13.19)ng/L,respectively,which were higher than those in the control group,and the differences between groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Kangfuxin Solution combined with pantoprazole in the treatment of chronic erosive gastritis can effectively reduce the inflammatory response of patients and regulate gastrointestinal hormones,it is safe and reliable,and can be popularized in clinic.